Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects

NCT04643795 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
87
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Madrigal Pharmaceuticals, Inc.